Thrombocytopenia is associated with severe retinopathy of prematurity
Authors:
- Bertan CakirBCBertan Cakir
- Raffael LieglRLRaffael Liegl
- Gunnel HellgrenGHGunnel Hellgren
- Pia LundgrenPia Lundgren
- Ye SunYSYe Sun
- Susanna KlevebroSKSusanna Klevebro
- Clara MannheimerCMClara Mannheimer
- Steve ChoSCSteve Cho
- Alexander PobleteAPAlexander Poblete
- Rubi DuranRDRubi Duran
- Boubou HallbergBHBoubou Hallberg
Open Access
- 4 October 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (19)
Abstract
Retinopathy of prematurity (ROP) is characterized by abnormal retinal neovascularization in response to vessel loss. Platelets regulate angiogenesis and may influence ROP progression. In preterm infants, we assessed ROP and correlated with longitudinal postnatal platelet counts ( n = 202). Any episode of thrombocytopenia (9 /l) at ≥30 weeks postmenstrual age (at onset of ROP) was independently associated with severe ROP, requiring treatment. Infants with severe ROP also had a lower weekly median platelet count compared with infants with less severe ROP. In a mouse oxygen-induced retinopathy model of ROP, platelet counts were lower at P17 (peak neovascularization) versus controls. Platelet transfusions at P15 and P16 suppressed neovascularization, and platelet depletion increased neovascularization. Platelet transfusion decreased retinal of vascular endothelial growth factor A (VEGFA) mRNA and protein expression; platelet depletion increased retinal VEGFA mRNA and protein expression. Resting platelets with intact granules reduced neovascularization, while thrombin-activated degranulated platelets did not. These data suggest that platelet releasate has a local antiangiogenic effect on endothelial cells to exert a downstream suppression of VEGFA in neural retina. Low platelet counts during the neovascularization phase in ROP is significantly associated with the development of severe ROP in preterm infants. In a murine model of retinopathy, platelet transfusion during the period of neovascularization suppressed retinopathy.Keywords
Funding Information
- NIH, European Commission FP7 project, (305485 PREVENT-ROP)
- NIH, European Commission FP7 project, (NIH EY024864)
- NIH, European Commission FP7 project, (EY017017)
- NIH, European Commission FP7 project, (P01 HD18655)
- NIH, European Commission FP7 project, (P01 HL046925)
- NIH, European Commission FP7 project, (HL69990)
This publication has 38 references indexed in Scilit:
- Thrombocytopenia and retinopathy of prematurityJournal of American Association for Pediatric Ophthalmology and Strabismus, 2011
- Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesisBlood, 2011
- The α‐granule proteome: novel proteins in normal and ghost granules in gray platelet syndromeJournal of Thrombosis and Haemostasis, 2010
- DO PLATELETS HAVE A ROLE IN THE PATHOGENESIS OF AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY?Retina, 2010
- Computer-aided quantification of retinal neovascularizationAngiogenesis, 2009
- Platelet Granule Secretion Continuously Prevents Intratumor HemorrhageCancer Research, 2008
- Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially releasedBlood, 2008
- Proteomic analysis of platelet α‐granules using mass spectrometryJournal of Thrombosis and Haemostasis, 2007
- Angiogenesis: an organizing principle for drug discovery?Nature Reviews Drug Discovery, 2007
- Evidence that platelets promote tube formation by endothelial cells on matrigelBritish Journal of Pharmacology, 1998